Works matching AU SUN JIN SYM

Results: 43
    1
    2
    3

    Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma.

    Published in:
    Oncology (08909091), 2023, v. 37, n. 4, p. 175
    By:
    • Catenacci, Daniel V. T.;
    • Yoon-Koo Kang;
    • Uronis, Hope E.;
    • Keun-Wook Lee;
    • Ng, Matthew C. H.;
    • Enzinger, Peter C.;
    • Se Hoon Park;
    • Gold, Philip J.;
    • Lacy, Jill;
    • Hochster, Howard S.;
    • Sang Cheul Oh;
    • Yeul Hong Kim;
    • Marrone, Kristen A.;
    • Kelly, Ronan J.;
    • Juergens, Rosalyn A.;
    • Jong Gwang Kim;
    • Alcindor, Thierry;
    • Sun Jin Sym;
    • Eun-Kee Song;
    • Cheng Ean Chee
    Publication type:
    Article
    4

    Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).

    Published in:
    Gastric Cancer, 2018, v. 21, n. 5, p. 819, doi. 10.1007/s10120-018-0806-1
    By:
    • Jung, Minkyu;
    • Ryu, Min-Hee;
    • Oh, Do Youn;
    • Kang, Myounghee;
    • Zang, Dae Young;
    • Hwang, In Gyu;
    • Lee, Keun-Wook;
    • Kim, Ki Hyang;
    • Shim, Byoung Yong;
    • Song, Eun Kee;
    • Sym, Sun Jin;
    • Han, Hye Sook;
    • Park, Young Lee;
    • Kim, Jin Soo;
    • Lee, Hyun Woo;
    • Lee, Moon Hee;
    • Koo, Dong-Hoe;
    • Song, Hong Suk;
    • Lee, Namsu;
    • Yang, Sung Hyun
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12

    Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).

    Published in:
    Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211042812
    By:
    • Han, Hye Sook;
    • Kim, Bum Jun;
    • Jee, Hee-Jung;
    • Ryu, Min-Hee;
    • Park, Se Hoon;
    • Rha, Sun Young;
    • Kim, Jong Gwang;
    • Bae, Woo Kyun;
    • Lee, Keun-Wook;
    • Oh, Do-Youn;
    • Kim, In-Ho;
    • Sym, Sun Jin;
    • Oh, So Yeon;
    • Kim, Hyeong Su;
    • Byun, Ji-Hye;
    • Kim, Dong Sook;
    • Suh, Young Ju;
    • An, Hyonggin;
    • Zang, Dae Young
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).

    Published in:
    Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211042812
    By:
    • Han, Hye Sook;
    • Kim, Bum Jun;
    • Jee, Hee-Jung;
    • Ryu, Min-Hee;
    • Park, Se Hoon;
    • Rha, Sun Young;
    • Kim, Jong Gwang;
    • Bae, Woo Kyun;
    • Lee, Keun-Wook;
    • Oh, Do-Youn;
    • Kim, In-Ho;
    • Sym, Sun Jin;
    • Oh, So Yeon;
    • Kim, Hyeong Su;
    • Byun, Ji-Hye;
    • Kim, Dong Sook;
    • Suh, Young Ju;
    • An, Hyonggin;
    • Zang, Dae Young
    Publication type:
    Article
    25
    26
    27
    28
    29
    30

    Erratum to: Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.

    Published in:
    2017
    By:
    • Kim, Jeong;
    • Jang, Joung-Soon;
    • Kim, Jae-Weon;
    • Lee, Sung;
    • Cho, Chi-Heum;
    • Lee, Myung-Ah;
    • Kim, Do-Jin;
    • Ahn, Myung-Ju;
    • Lee, Kil;
    • Sym, Sun;
    • Lim, Myong;
    • Jung, Hun;
    • Kim, Cho;
    • Min, Kyung;
    • Kim, Jeong Eun;
    • Lee, Sung Yong;
    • Lee, Kil Yeon;
    • Sym, Sun Jin;
    • Lim, Myong Choel;
    • Kim, Cho Eun
    Publication type:
    journal article
    31

    Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.

    Published in:
    2017
    By:
    • Kim, Jeong;
    • Jang, Joung-Soon;
    • Kim, Jae-Weon;
    • Sung, Yong;
    • Cho, Chi-Heum;
    • Lee, Myung-Ah;
    • Kim, Do-Jin;
    • Ahn, Myung-Ju;
    • Lee, Kil;
    • Sym, Sun;
    • Lim, Myong;
    • Jung, Hun;
    • Cho, Eun;
    • Min, Kyung;
    • Kim, Jeong Eun;
    • Sung, Yong Lee;
    • Lee, Kil Yeon;
    • Sym, Sun Jin;
    • Lim, Myong Choel;
    • Cho, Eun Kim
    Publication type:
    journal article
    32
    33

    Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

    Published in:
    Gastric Cancer, 2024, v. 27, n. 6, p. 1287, doi. 10.1007/s10120-024-01535-0
    By:
    • Boku, Narikazu;
    • Omori, Takeshi;
    • Shitara, Kohei;
    • Sakuramoto, Shinichi;
    • Yamaguchi, Kensei;
    • Kato, Ken;
    • Kadowaki, Shigenori;
    • Tsuji, Kunihiro;
    • Ryu, Min-Hee;
    • Oh, Do-Youn;
    • Oh, Sang Cheul;
    • Rha, Sun Young;
    • Lee, Keun-Wook;
    • Chung, Ik-Joo;
    • Sym, Sun Jin;
    • Chen, Li-Tzong;
    • Chen, Jen-Shi;
    • Bai, Li-Yuan;
    • Nakada, Takashi;
    • Hagihara, Shunsuke
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43